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FORMATION OF SLOW-REACTING SUBSTANCE OF 
ANAPHYLAXIS IN HUMAN LUNG TISSUE AND CELLS 
BEFORE RELEASE* 
BY ROBERT A. LEWIS,$ STEPHEN I, WASSERMAN,$ EDWARD J. GOETZL,§ hND K. 
FRANK AUSTEN 
(From the Departments ofMedicine, Harvard Medical School and Robert B. Brigham Hospital, 
Boston, Massachusetts 02120) 
Slow-reacting substance of anaphylaxis (SRS-A) ~ is an acidic, sulfur-containing chemical 
mediator with an approximate tool wt of 500-600 (1, 2), which is released during 
immediate hypersensitivity reactions and has the capacity to increase vascular permeabil- 
ity (3) and to contract certain smooth muscle preparations (4). The release of SRS-A in 
vitro was initially detected by analysis of the perfusates obtained from sensitized guinea 
pig heart-lung preparations (5, 6) and the diffusates of isolated segments of guinea pig 
lung (7) challenged with specific antigen. Subsequently, SRS-A was released in vivo into 
the peritoneal cavity of the hyperimmunized rat by intraperitoneal challenge (8) and into 
the plasma of the sensitized guinea pig undergoing systemic anaphylaxis in response to 
intravenous antigen (9). Studies with passively sensitized guinea pig (10) and primate 
lung fragments, monkey (11) or human (12, 13), demonstrated that IgG1 and IgE, 
respectively, prepared the tissues for subsequent antigen-induced release of SRS-A. More 
recently, material with the functional activity of SRS-A has been released by antigen 
challenge of sensitized monkey lung suspensions containing mast cells (14) and human 
leukocyte preparations rich in sensitized basophils (15, 16). SRS-A has not been detected 
in tissues (7) or cells, normal or sensitized, as  preformed chemical mediator; and its 
release in vitro occurs more slowly than that of the preformed chemical mediators, 
histamine and eosinophil chemotactic factor of anaphylaxis (ECF-A) (7, 17), consistent 
with a requirement for formation before release. 
Although knowledge of the physicochemical characteristics of SRS-A and the 
immunoglobul ins and critical cell types responsible for its release has evolved, 
there has been no demonstrat ion of its cellular generation before release. 
Alteration of the tissue extraction procedure for residual mediators by the 
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~Abbreviations used in this paper: DFP, diisopropyl fluorophosphate; ECF-A, eosinophil 
chemotactic factor of anaphylaxis; SAG, atopic serum from a ragweed-sensitive patient; SRS-A, 
slow-reacting substance of anaphylaxis. 
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ins t i tu t ion  of  f reeze- thawing  six t imes  to e l iminate  bo i l ing  or ac id  t reatment  
revea led  the  accumulat ion  of SRS-A  a f te r  an  IgE -dependent  react ion  in lung  
f ragments  or  i so la ted  lung  cel ls .  Thus ,  it  was  poss ib le  for the  f i rs t  t ime to  de f ine  
the  t ime-course  of  the  in t race l lu la r  fo rmat ion  of  SRS-A  wh ich  precedes  i ts  
re lease .  
Materials and Methods 
Chymopapain, collagenase, and catalase (Worthington Biochemical Corp., Freehold, N. J.), elastase 
(Sigma Chemical Co., St. Louis, Mo.), pronase, deoxyribonuclease, and N6,O~dibutyryl cyclic 
3',5'-adenosine monophosphate (dibutyryl cyclic AMP, Calbiochem, San Diego, Calif.), gelatin 
(Difco Laboratories, Detroit, Mich.), sodium metrizoate (Triosil-75, Glaxo Laboratories, Ltd., Green- 
ford, England), sodium diatrizoate (Hypaque, Winthrop Laboratories, New York), Ficoll (Pharmacia 
Fine Chemicals, Inc., Piscataway, N. J.), silicic acid (100-200 mesh) and Amberlite XAD-2 (Mal- 
linekrodt Chemical Works, St. Louis, Mo.), histamine acid phosphate (Mann Research Labs, Inc., 
New York), atropine sulfate (Sigma Chemical Co.), mepyramine maleate (Merck, Sharp & Dohme, 
West Point, Pa.), no. 80 brass sieve (Matheson Scientific, Inc., Stoneham, Mass.), 8/~m pore-size 
micropore filters (Millipore Corp., Bedford, Mass.), and five times recrystallized ovalbumin (Miles 
Laboratories, Inc., Miles Research Div., Kankakee, Ill.) were purchased from the manufacturers. 
Ficoll-Hypaque cushions were made as described by BSyum (18). Ragweed antigen E (Research Re- 
sources Branch, NIAID, Bethesda, Md.), and 8-bromo-cyclic 3',5'-guanosine monophosphate (8- 
bromo-cyelic GMP, L. Simon, ICN Nucleic Acid Research Institute, ICN Corp., Irvine, Calif.) were 
provided as noted. All solvents used in silicic acid chromatography of SRS-A were of nanograde 
quality. The atopic serum from a ragweed-sensitive patient (SAG) had a concentration of250 ng IgE 
protein/ml by radioimmunodiffusion (19). Rabbit antihuman lgE, provided by Dr. Peter H. Schur, 
Robert B. Brigham Hospital, Boston, Mass., was made against purified Shackford IgE myeloma (20), 
precipitated in 40% ammonium sulfate, and then subjected to immunoabsorption with normal human 
serum coupled to Sepharose 6B (21). The absorbed rabbit anti-IgE gave no precipitin lines on immuno- 
electrophoretic analysis with normal human serum. Tyrode's buffer (22) was used throughout unless 
otherwise noted. 
Mediator Bioassays. The isolated atropinized guinea pig ileum was used to bioassay histamine, 
and the same preparation with the addition of an antihistamine was employed to quantitate SRS-A 
(10). Prostaglandin activity was assayed on the isolated ascending colon of the gerbil (23). ECF-A was 
assessed by a modification (24) of the Boyden chamber chemotactic technique (25) with purified 
human eosinophils (26). 
SRS-A in diffusates or extracts of tissue or cells was characterized further by purification (1) of 
activity extracted into 80% ethanol. The extract was centrifuged at 19,000 g for 10 min at 4°C; and the 
supernate was flask evaporated, resuspended in distilled water, exposed to 0.1 N NaOH at 37°C for 30 
min, and applied to a 10 ml Amberlite XAD-2 column. After a water wash of 30 ml, the activity was 
eluted with 30 ml of 80% ethanol, flask evaporated, resuspended in 1.1 ml of 100% ethanol, and 
applied to a 10 ml silicic acid column. 30 ml of each of the following solvents were then applied in a 
stepwise fashion: hexane, methylene chloride, acetone, n-propanol, and ethanol:concentrated 
ammonia:water (in a 6:3:1 vol/vol ratio). Each 30-ml eluate was flask evaporated and suspended in 
Tyrode's buffer for bioassay. 
IgE-Dependent Reactions in Human Lung Fragments and Cell Preparations. Specimens of 
grossly normal-appearing human lung were obtained from patients at the time of surgery for lung 
cancer. The lung tissue was washed and fragmented as previously described (13). Reversed 
anaphylactic mediator elease was carried out with duplicate 250- or 500-mg portions of replicate 
fragments incubated with a final dilution of 1:50 rabbit antihuman IgE in a vol of i ml at 37°C for the 
time period stated. For direct anaphylactic mediator release from passively sensitized lung 
fragments, 250- or 500-mg replicates were sensitized in 1 ml of SAG serum diluted 1:3 for 18 h at room 
temperature, washed three times, and challenged at 37°C with 200 ng ragweed antigen E in a final vol 
of i ml for the time stated. To terminate ither direct or reversed release, the reaction mixtures were 
brought o 3 ml with iced Tyrode's buffer, and the supernates were decanted from the fragments. The 
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tissues were resuspended in 3 ml of Tyrode's buffer and freeze-thawed six times in a dry ice-acetone 
bath to disrupt he cells and recover the mediators for bioassay. 
The method of Gould et al. (27) to isolate rabbit lung cells was applied with minor modifications to
human lung. Washed human lung fragments suspended in Tyrode's buffer were exposed to 2.0 mg/ml 
pronase and 0.5 mg/ml chymopapain for 20 rain at 37°C with stirring. Freed cells were separated 
from residual fragments by sieving through a no. 80 brass fine wire-mesh sieve and were washed three 
times in Tyrode's buffer. The residual fragments were treated with 1.0 mg/ml collagenase. 10.0 U/ml 
elastase, 0.03 mg/ml deoxyribonuclease, and 0.1 mg/ml catalase for 20 min at 37°C with stirring. 
Freed cells were again separated from the residual fragments by sieving and washing, and the cells 
from both digestion steps were combined and diluted to 107 nucleated cells/ml in Tyrode's olution 
made in 0.1 g/100 ml in gelatin (Tyrode's gelatin). 2.5 ml of cell suspension were layered over 2.5 ml of 
FicolbHypaque and centrifuged at 400 g for 30 min at room temperature. Cells at the Tyrode's-Ficoll- 
Hypaque interface were aspirated with an 18-gauge needle, while cells in the pellet at the bottom of 
the tube were obtained by resuspension after the fluid layers had been discarded. Cells from the 
interface were identified with Wright's stain or toluidine blue as mast cells, macrophages, 
lymphocytes, lung parenchymal cells, and lung stromal cells, with only minor erythrocyte 
contamination; these cells contained more than 70% of the histamine and ECF-A in the starting 
mixture. Cells sedimenting to the bottom were predominantly erythrocytes and polymorphonuclear 
leukocytes and contained less than 5% of the original histamine and ECF-A. Cells from the interface 
were resuspended in Tyrode's gelatin and, after three washes to remove the Ficoll-Hypaque, were 
used for mediator elease. In passive sensitization experiments, 25 × 106 cells were incubated in 
duplicate in a 1-ml vol of SAG serum diluted 1:3 at 37°C for 90 min, washed three times with Tyrode's 
gelatin, and then challenged with 200 ng of ragweed antigen E at 37°C for 30 min in a final vol of 1 ml 
Tyrode's gelatin unless otherwise noted. In reversed anaphylactic mediator release, 25 × 10 e cells 
were incubated in duplicate in 1 ml of rabbit antihuman IgE in a final dilution of 1:50 for the time 
indicated. In order to terminate the release reactions, the suspensions were diluted to 3 ml by the 
addition of iced Tyrode's gelatin, and the cells were sedimented at 400 g for 5 min at room 
temperature. The supernates were decanted and the cell pellets resuspended in 3 ml of Tyrode's 
gelatin and freeze-thawed in a dry ice-acetone bath six times. Both supernates and tissue or cell 
extracts were assayed for the mediators of immediate hypersensitivity. The quantities of SRS-A in 
supernates and cell extracts were expressed as units obtained from the cells freed from 10 g of lung 
tissue (U/10 g lung equivalent). The number of lung cells freed and recovered after Ficoll-Hypaque 
purification varied from 15 to 50 × 106 cells/10 g of lung tissue with 4-8% being mast cells. 
Results 
SRS-A Generation and Release. The knowledge that  SRS-A  was not a 
pre formed med ia tor  but yet appeared in the di f fusate wi th in  minutes  after an 
immediate - type  hypersens i t iv i ty  react ion in t issue impl ied  e i ther  a br ief  period 
of in t race l lu lar  residence, ext race l lu lar  format ion,  or a fai lure of exist ing 
methodolog ies  to extract  SRS-A  in its t issue phase, The previously employed 
techn iques  of boi l ing for 10 min  in Tyrode 's  buffer wi th or w i thout  ac id i f icat ion 
(7) as well as a f reeze- thawing procedure adopted  for the extract ion of ECF-A  
(28) were used to seek SRS-A  in normal  and sensi t ized lung t issue before and 
after chal lenge.  Sens i t ized t issues exposed to specif ic ant igen not only released 
SRS-A  into the supernate  but  disclosed t issue SRS-A  wi th  extract ion by the 
f reeze- thawing technique.  Accordingly,  it was possible to examine  the cel lu lar  
generat ion of SRS-A  before its release from human lung t issue or isolated cells by 
d i rect  and reversed anaphy lac t i c  react ions.  
ACTIVATION BY ANTI-IgE. The t ime-course  of tota l  SRS-A  generat ion in human 
lung fragments,  as determined  by the sum of the SRS-A  remain ing  in the t issues 
and that  re leased into the supernate  after chal lenge of the t issues with ant i - IgE  is 
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shown in Fig. 1. SRS-A was undetectable in the tissues at time zero and 
accumulated rapidly, reaching the maximum tissue level observed within 2 min 
after the addition of anti-IgE. In contrast, SRS-A release into the supernate was 
not evident until 2-5 min and proceeded to increase until 10 rain, reflecting 
continued generation. Histamine release occurred within the 1st min and reached 
near maximum at 2 min, paralleling cellular SRS-A generation before release. 
Isolated cells challenged with the 1:50 dilution of anti-IgE (Fig. 2) demon- 
strated an accumulation of cellular SRS-A at 1 min with a plateau at 2 min. 
Release of SRS-A began concomitant with cellular accumulation and proceeded 
to rise throughout the 30 min of observation, implying continued generation. 
ECF-A and histamine release (not shown) were maximal at 2 min, reaching, 
respectively, 34% and 18% net total release, and plateauing with cellular SRS-A 
at a time when SRS-A generation was continuing. In two additional experiments, 
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Fro. 1. Time-course of generation and release of SRS-A from human lung fragments challenged with 
anti-IgE. Ill, SRS-A residual; r'q, SRS-A release; A, SRS-A total; and Q, histamine release. 
cellular SRS-A again plateaued at approximately 2 min, with generation 
continuing as assessed by increasing release for 15-30 min. 
The failure to demonstrate he accumulation of SRS-A in cells before release 
by a 1:50 dilution of anti-IgE in kinetic experiments prompted an alternative 
approach in which the intensity of the reversed anaphylactic activation was 
varied. Isolated cells challenged with a 1:1,000 or 1:2,000 dilution of anti-IgE 
accumulated SRS-A without release (Fig. 3). As the antibody concentration was 
increased to 1:100 or 1:200, there was an approximately equal distribution of 
SRS-A between cells and supernate, while with a 1:20 dilution of anti-IgE, all of 
the SRS-A detected was in the supernate. As the total SRS-A generated, the sum 
of that in the cells and supernate, was essentially the same with antibody 
concentrations from 1:200 to 1:20, and approximately three times that in the cells 
activated with antibody concentrations of 1:1,000 or 1:2,000, it is evident hat the 
intensity of activation influences both the total quantity of SRS-A generated and 
the percentage r leased at 30 min. 
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F](;. 2. Time-coume of generation and release of SRS-A from isolated human lung cells challenged 
with anti-IgE.., SRS-A residual; D, SRS-A release; and A, SRS-A total. 
FIG. 3. SRS-A generation and release from isolated human lung cells challenged for 30 min by varying 
concentrations of anti-IgE. 
ACTIVATION BY IgE-ANTIGEN INTERACTION. The time-course of total SRS-A gen- 
eration in passively sensitized human lung fragments as determined by the sum 
of SRS-A accumulated in the tissue and that  released into the diffusate after 
antigen challenge is depicted in Fig. 4. SRS-A was undetectable in the sensitized 
tissues at t ime zero, but accumulated rapidly after antigen challenge, reaching 
the max imum tissue level observed within 2 min. On the other hand, SRS-A 
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FIG. 4. Time-course of SRS-A generation and release from passively sensitized human lung fragments 
challenged with antigen E. l ,  SRS-A residual; El, SRS-A release; A, SRS-A total; and 0, histamine re- 
lease. 
release into the diffusate was not evident until 2-5 min after antigen challenge 
and increased over 15 min, reflecting continued generation. Histamine release 
began within the 1st min and reached near maximum at 2 min, paralleling 
SRS-A generation before release. 
Isolated passively sensitized lung cells challenged with specific antigen 
resembled the whole tissue in demonstrating a lag time between the accumula- 
tion of SRS-A in cells and its release (Fig. 5). SRS-A was undetectable in the cells 
at time zero, but appeared rapidly, reaching the maximum level observed by 1 
rain. Release into the supernate was not evident until 5 min and increased until 
30 min, reflecting continued generation. Histamine release was maximal at 2 
rain, paralleling cellular SRS-A generation before release. 
In order to examine the relationship between the magnitude of passive 
sensitization as assessed by antigen-induced histamine release and the genera- 
tion of SRS-A, isolated lung cells were passively sensitized with varying doses of 
atopic serum (Fig. 6) and challenged with a fixed dose of antigen. While cells 
interacted with dilutions of 1:4 and 1:2 of atopic serum released histamine upon 
antigen challenge, those interacted with dilutions of 1:16 and 1:8 did not, 
implying that the lesser concentrations of IgE failed to sensitize the target cells. 
On the other hand, cells interacted with 1:16 and 1:8 dilutions of antiserum 
accumulated SRS-A after antigen challenge in the absence of SRS-A release. 
Unsensitized and antigen-exposed cells did not contain SRS-A. Thus, as with 
reversed anaphylactic challenge, the cellular accumulation of SRS-A without 
release reflects a minimal but definite immunologic activation. Sensitization at 
the greater concentrations of atopic serum followed by antigen challenge was not 
only accompanied by release of SRS-A into the supernate, but also by an 
incremental increase in total SRS-A generation. 
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Fro. 5. Time-course of SRS-A generation and release from passively sensitized isolated human lung 
cells challenged with antigen E. I ,  SRS-A residual; El, SRS-A release; A, SRS-A total; and El, hista- 
mine. 
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Fro. 6. SRS-A generation and release from isolated human lung cells passively sensitized with varying 
concentrations of atopic serum and challenged with specific antigen. I ,  SRS-A residual; El, SRS-A re- 
lease; A, SRS-A total; and 0, histamine release. 
Partial Purification of Extracted and Released SRS-A. In order to establish 
that the material extracted and released and designated as SRS-A by bioassay on 
the atropinized antihistamine-treated guinea pig ileum did indeed represent 
SRS-A activity, partial purification (1) was carried out (Table I). In this 
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TABLE I 
Partial Purification of SRS-A* 
Procedure 
Recovery of 
Recovery of 
supernatant residual SRS-A 
SRS-A 
Starting material 
Ethanol extraction 
0.1 N NaOH (37°C × 30 min); Am- 
berlite XAD-2 chromatography 
Silicic acid chromatography: 
Hexane 
Methylene chloride 
Acetone 
n-Propanol 
Ethanol:concentrated mmonia: 
water (6:3:1, vol/vol) 
U U 
100 240 
75 225 
65 180 
<5 <5 
<5 <5 
<5 <5 
<5 <5 
35 i00 
*Generated from a single 250-mg portion of passively sensitized human 
lung fragments 30 min after antigen challenge as described in the Mate- 
rials and Methods. 
procedure, cleavage of phospholipids is accomplished by base hydrolysis; 
histamine, serotonin, and the kinins are removed by their elution in the water 
wash from Amberlite XAD-2; and prostaglandins are extracted in hexane and 
acetone during silicic acid chromatography. SRS-A is stable to base hydrolysis, 
elutes in 80% ethanol on Amberlite XAD-2 chromatography, and remains on the 
silicic acid until the application of ethanol:concentrated ammonia:water (6:3:1). 
As shown in Table I, the recovery of SRS-A was 35 of 100 U in the initial super- 
nate and 100 of 240 U~in the initial extract of residual mediator. Although a 35- 
42% recovery is somewhat less than that observed when 1,000 times as much 
material was processed (1), it is completely characteristic of the recoveries 
repeatedly obtained with small-scale purification. A similar recovery was 
observed for supernatant and cellular SRS-A recovered from tissues or isolated 
cells challenged with anti-IgE. 
Modulation of SRS-A Generation by Action of Cyclic Nucleotides. The 
capacity to measure total SRS-A generation as the sum of that in the tissues and 
that released into the supernate prompted an analysis of the effect of cyclic 
nucleotides upon the generation of SRS-A. It had previously been observed that 
the endogenous elevation of cyclic AMP or the addition of exogenous dibutyryl 
cyclic AMP inhibited SRS-A release (13, 29), while cholinergic stimulation or the 
introduction of 8-bromo-cyclic GMP enhanced release (19); but these experi- 
ments did not distinguish an action on generation separate from release. Human 
lung fragments that were passively sensitized revealed no detectable SRS-A after 
2- or 30-min incubation in buffer, while antigen challenge resulted in generation 
of 30 U of SRS-A/g lung tissue at 2 min and 280 U/g at 30 min (Fig. 7). At 2 min, 
none of the SRS-A generated had been released into the fluid, while at 30 min, 
approximately 67% had been discharged. Preincubation of the fragments for 20 
min with 10 -3 M dibutyryl cyclic AMP completely prevented SRS-A generation 
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Fro. 7. Cyclic nucleotide modulation of SRS-A generation from passively sensitized human lung frag- 
ments. 
at 2 and 30 min, in that no SRS-A was extractable from the tissue and none was 
found in the supernate. Preincubation of the fragments for 20 min with 10 _8 M 
8-bromo-cyclic GMP increased SRS-A generation at 2 min from 30 to 80 U and at 
30 min from 280 to 390 U. Despite the 2.5-fold increase in SRS-A generation at 2 
min, the product was entirely within the tissues, while at 30 min, 75% of that 
generated had been released. 
Discussion 
The capacity to extract SRS-A from human lung tissue or cells after immuno- 
logic activation and the measurement of SRS-A in both the extract and the 
surrounding fluid permit an analysis of SRS-A generation. That the SRS-A 
extracted was not merely trapped in interstitial spaces after release was indicated 
by its detection ot only within tissue (Figs. 1 and 4) but within isolated washed 
cells after activation by reversed (Figs. 2 and 3) or direct (Figs. 5 and 6) 
anaphylaxis. The propensity of SRS-A to adsorb to a variety of surfaces as well as 
to certain plasma proteins (4, 30) does not account for its extraction from cells, 
since thorough washing did not diminish its association with the cell fraction 
and, more importantly, the total SRS-A generated id not bear a fixed 
relationship to the fraction remaining within the cells (Fig. 3). Further, under 
three circumstances the SRS-A detected was entirely intracellular, implying that 
release had not yet occurred. These conditions included: the initial 1-2 min of 
SRS-A generation after activation by reversed anaphylaxis (Fig. 1) in lung frag- 
ments and by direct anaphylaxis n passively sensitized lung fragments (Fig. 4) 
and isolated cells (Fig. 5); the response of isolated cells to limited immunologic 
activation as achieved by challenge with low doses of anti-IgE (Fig. 3) or passive 
sensitization with low concentrations of atopic serum before antigen challenge 
(Fig. 6); and the action of exogenous 8-bromo-cyclic GMP which yielded a 
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2.5-fold increase in the quantity of SRS-A generation without release at 2 min in 
passively sensitized antigen-challenged lung fragments (Fig. 7). 
That the material extracted was indeed SRS-A was established by both 
differential bioassay and purification. Both the tissue and cell extract and 
supernatant SRS-A failed to contract the isolated gerbil colon (23) at a 
concentration five times that yielding a 1 U response on the isolated guinea pig 
ileum pretreated with atropine and antihistamine. During purification of the 
ethanol extract of tissues, cells, or diffusates, all contractile activity for the 
isolated atropinized antihistamine-treated guinea pig ileum eluted with ethanol 
from Amberlite XAD-2 and not with distilled water. Further, during silicic acid 
chromatography, no activity appeared with solvents capable of eluting prosta- 
glandins, and recovery was limited to the solvent previously established as 
selectively eluting SRS-A (1). 
The quantitation of SRS-A in tissues and cells as well as in the surrounding 
medium introduces an additional dimension to the study of SRS-A generation 
and may well clarify certain previously recognized ifferences between the 
elaboration of this mediator and those known to be preformed. The capacity of 
certain pharmacologic agents such as diisopropyl fluorophosphate (DFP) (31), 
isoproterenol in the presence of carbamylcholine (32), and the cytochalasins A 
and B (33) to suppress SRS-A release without affecting or even enhancing 
histamine release may well be explicable by an action or formation with or 
without an additional effect on release. Treatment of lung fragments with DFP 
(31) followed 3-5 min later by washing and antigen challenge permitted 
histamine release may well be explicable by an action or formation with or 
release if antigen challenge was carried out in the presence of DFP. Thus, the 
release of histamine requires the activation of an esterase from its DFP-resistant 
precursor form (34). In contrast, removal of DFP before antigen challenge did not 
relieve the inhibitory effect on SRS-A release (31, 34), implying that its 
generation i volves an already active esterase. Stimulation of lung tissue with a 
fixed dose of isoproterenol sufficient to give a 10-fold increase in total tissue cyclic 
AMP completely prevented the subsequent appearance ofhistamine and SRS-A 
in the diffusate after antigen challenge. The treatment of replicate fragments 
with increasing doses of the cholinomimetic agent carbamylcholine progressively 
reversed the inhibition of histamine release and, at the highest dose, yielded 
enhancement. In contrast, there was little diminution of the isoproterenol-in- 
duced rise in total tissue cyclic AMP and no reversal of the total suppression of 
SRS-A release (32). In view of the suppression of SRS-A generation by cyclic 
AMP (Fig. 7), it may well be that the capacity of cholinergic stimulation to 
reverse adrenergic effects is more readily observed upon the secretory phase of 
mediator release than upon the generation of SRS-A. Similarly, the cyto- 
chalasins A and B, with an apparent site of action distinctly different from DFP 
or the cyclic nucleotides, suppressed the release of SRS-A at concentrations 
which fully permitted or even facilitated histamine release (33). As in each 
instance it is SRS-A release that fails to occur in association with histamine 
release, the observations could be unified by preferential ction of the agents on 
SRS-A formation. 
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Another finding was that the intensity of the immunologic stimulus appeared 
to determine both the quantity of the SRS-A generated and its distribution 
between the cells and the fluid phase. Indeed, the presence of cellular SRS-A was 
a more sensitive index of immunologic activation than its detection in the 
surrounding fluid. Challenge of unsensitized cells with low concentrations of
anti-IgE (Fig. 3) or sensitization with low concentrations of atopic serum followed 
by antigen challenge (Fig. 6) resulted in the accumulation of cellular SRS-A 
without release. Antigen-induced SRS-A formation in lung cells was observed 
without either histamine or SRS-A release (Fig. 6). Although the possibility of a 
preferential inactivation of mediators after release cannot be excluded, there is 
no evidence to support such an interpretation. As the intensity of the immuno- 
logic activation increased, there was not only a progressive shift of the detectable 
SRS-A to the surrounding medium, but also an increased generation (Figs. 3 and 
6). 
An additional consideration i the study of SRS-A generation relates to the 
possibility of more than one intracellular source or more than one cell source, 
either by primary immunologic activation or secondary to the action of a primary 
chemical mediator on a second cell. Such a possibility is introduced because of 
the continued generation of SRS-A at a time when the tissue (Figs. 1 and 4) or 
cellular (Figs. 2 and 5) content has plateaued and the release of preformed 
mediators i complete. The release of platelet-activating factor is an example of a 
primary mediator recruiting additional mediators through an effect on a second 
cell (35). The release of SRS-A from the rat peritoneal cavity by both IgE and 
mast cell-dependent (36) and IgGa, complement, and polymorphonuclear leuko- 
cyte-dependent (37) mechanisms illustrates that more than one cell type can 
participate in its generation. Another alternative is that the IgE immunoglobu- 
lins bound to mast cells or basophils in excess of those required for optimal 
release of preformed mediators interact with antigen to perturbate the membrane 
with resultant SRS-A generation i dependent of intracellular accumulation orof 
the discharge of preformed mediators. 
Summary 
The capacity to extract slow-reacting substance of anaphylaxis (SRS-A) from 
human lung tissue or cells after immunologic activation, together with the 
measurement of SRS-A in both the extract and the surrounding fluid, permits 
study of total SRS-A generation. That the material extracted is SRS-A was 
established by both differential bioassay and purification. SRS-A accumulation 
was entirely intracellular after limited IgE-dependent direct or reversed ana- 
phylactic activation. Intracellular accumulation also generally preceded re- 
lease, with generation of SRS-A continuing well beyond a plateau in the cellular 
SRS-A level and the release of preformed mediators. The quantity of SRS-A 
generated after immunologic activation was modulated by the introduction of 
exogenous cyclic nucleotides, revealing a site of cyclic nucleotide action distinct 
from that on mediator release. The capacity to determine not only the release of 
preformed mediators but also the generation of a newly formed mediator, the 
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sum of SRS-A in cells and supernate, adds an additional dimension to the anal- 
ysis of the cellular events of immediate hypersensitivity. 
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